Key mechanistic steps are summarized in Scheme S1. Scheme S1: Key mechanistic steps of conjugation. The presence of the cluster has been omitted for clarity.
In the first step, carried out in pH 6 buffer, an EDC ester intermediate is formed but not isolated. Simultaneous addition of sNHS results in the formation of a sNHS ester that precipitates out of solution. The sNHS ester is cleaned and then allowed to react with 6-APA in pH 7 buffer, resulting in the formation of the conjugated cluster. Scheme S2, summarizes various reaction steps performed in a 2 mL microcentrifugation tube.
Scheme S2: Key steps in cluster conjugation.
Step 1. Start with 1,0 mL of 500 mM MES buffer solution.
Step 2: Add a) 50 µL of cluster solution (1.4 mg Ag/mL concentration estimated to contain a maximum of 3 µmol RALA in total) b) 20 mg free-base EDC (130 µmol) c) 2 mg sNHS (13 µmol)
Step 3: React for 60 minutes
Step 4: Centrifuge at 2000 rpm for five minutes to precipitate less soluble sNHS-cluster. Discard supernatant.
Step 5: Wash precipitate twice with 500 µL of distilled water.
Step 6: Dissolve precipitate in 1 mL of 1 M TEAA solution or 250 mM MES buffer
Step 7: React for 60 minutes.
Step 8: Centrifuge at 2000 rpm for five minutes to precipitate less soluble conjugated cluster. Discard supernatant. Wash precipitate four times with 500 µL of distilled water.
Step 9: Dissolve conjugated product in 500 µL 50 mM TEA solution for ESI-MS analysis or suitable buffer for antibiotic testing.
Ampicillin Conjugation
Results of conjugating the (Ag 29 LA 12 ) [3-] cluster to ampicillin are summarized in Figure S1 . The conjugate was obtained by substituting molar equivalents of ampicillin for 6-APA in the synthetic protocol. Liquid chromatography (LC) experiments were performed on an Eksigent nanoLC 2D system coupled to a Bruker micrOTOF time-of-flight mass spectrometer (MS). All separations were carried out using an Ace 300Å C18 HPLC column (0.5 mm x 150 mm, 3 µm particle size) (Advanced Chromatography Technologies Limited, Aberdeen, UK) maintained at ambient laboratory temperature. Mobile phases were prepared 400 mM hexfluoroisopropanol (HFIP) -15 mM triethylamine (TEA) in ddH2O (mobile phase A) and neat methanol (mobile phase B). All solvents for direct infusion and LC-MS were obtained from Fisher Scientific (Fairlawn, NJ). The flow rate used for all experiments was ten microliters per minute (µL/min). Injections -5.0 µL -were carried out by an Eksigent AS-1 autosampler configured with a 20-µL sample loop.
All reaction mixture samples were diluted 20x in mobile phase A. Direct infusion was carried out by loop injection (i.e., no column between autosampler and mass spectrometer) using a mobile phase composition of 95% MP A: 5% MP B.HPLC experiments were carried out using twenty-minute linear gradient methods with varied starting and ending mobile phase conditions.
After completion of the twenty-minute gradient, 100% methanol was rinsed through the column to remove any non-polar components for five minutes. This was then followed by a twenty minute reequilibration at initial method conditions. Mass spectrometer acquisition settings were identical for both direct infusion and LC-MS experiments. Data was acquired from m/z 100 -6,000. Ten-thousand spectra were summed per spectrum acquired. Nebulizer pressure was set to 4.0 bar. Nitrogen sheath gas was set to zero L/min. The endplate offset and capillary potentials were held at -1000 V and 3500 V, respectively. Capillary exit and skimmer voltage settings were -100 V and -33 V respectively. Lens 1 pre-pulse storage and transfer times were 35 µs and 140 µs, respectively. MCP detector voltage was increased to 2350 V (from 2100 V standard) for improved detection. Figure S2 : Overlaid LC-MS Base Peak Chromatogram Traces -Analysis of the Ag29LA12 reaction mixture. Red Trace= Ag29(LA)12. Blue Trace = Ag29(Lipoic Acid)11(Lipoic Acid-Glycine)1. Black Trace = Ag29(Lipoic Acid)10(Lipoic Acid-Glycine)2 Figure S3 : Averaged mass spectrum from under Ag29(Lipoic Acid)10(Lipoic Acid-Glycine)2 chromatographic peak (black trace in Figure S2 ) Figure S5 : Averaged mass spectrum from under Ag29(LA)12chromatographic peak (red trace in Figure   S2 ) 0 1 Figure S4 : Averaged mass spectrum from under Ag29(Lipoic Acid)11(Lipoic Acid-Glycine)1 chromatographic peak (blue trace in Figure S2 ) a The data of the dose-effect inhibition (%) was obtained from a phenotypic luciferase assay and were generated by the Origin software. Data are presented as the mean of three independent assays in duplicates. b Fraction affected CI (Fa-CI) plots was generated using CompuSyn software. CI=1 means additive effect, CI >1 is antagonistic effect, and CI <1 means synergy (red numbers). 
Summary of Synergy Evaluation

